Show simple item record

dc.contributor.authorHaran, A. M.
dc.contributor.authorJain, Y.
dc.contributor.authorHambrock, T.
dc.contributor.authorMurphy, L. R.
dc.contributor.authorCook, A.
dc.contributor.authorBrown, L. C.
dc.contributor.authorHoyle, Alex P
dc.contributor.authorSachdeva, Ashwin
dc.contributor.authorAli, S. A.
dc.contributor.authorAmos, C. L.
dc.contributor.authorSydes, M. R.
dc.contributor.authorAttard, G.
dc.contributor.authorParmar, M. K.
dc.contributor.authorJames, N. D.
dc.contributor.authorClarke, Noel W
dc.date.accessioned2023-01-24T10:32:25Z
dc.date.available2023-01-24T10:32:25Z
dc.date.issued2022en
dc.identifier.citationHaran AM, Jain Y, Hambrock T, Murphy LR, Cook A, Brown LC, et al. Differential treatment response with nodal metastases in metastatic hormone-sensitive prostate cancer (mHSPC) and evaluation of nodal (N) burden as a prognostic biomarker: Ancillary studies of the docetaxel and abiraterone acetate and prednisolone (AAP) phase III trials from STAMPEDE. Annals of Oncology. 2022 Sep;33(7):S1161-S2. PubMed PMID: WOS:000866211601616.en
dc.identifier.doi10.1016/j.annonc.2022.07.1946en
dc.identifier.urihttp://hdl.handle.net/10541/625974
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.annonc.2022.07.1946en
dc.titleDifferential treatment response with nodal metastases in metastatic hormone-sensitive prostate cancer (mHSPC) and evaluation of nodal (N) burden as a prognostic biomarker: Ancillary studies of the docetaxel and abiraterone acetate and prednisolone (AAP) phase III trials from STAMPEDEen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentGenito-Urinary Cancer Research Group, The University of Manchester, Manchester,UKen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record